INTRODUCTION
The management of the neck in patients with head and neck cancer has been a topic of controversy for many years. 1 Historically, patients who were irradiated with intact lymph node disease were treated with a "planned" neck dissection after their radiotherapy. This concept was espoused due to a relatively high rate of neck recurrences in patients treated with radiotherapy alone, and the belief that clinical response was inadequate to determine the efficacy of treatment. 2 Imaging was ultimately incorporated into restaging patients, and the predictive value of computed tomography (CT) imaging 3 and subsequently positron emission tomography (PET) imaging 4 in determining whether a patient has residual disease shifted the neck management paradigm from one that routinely incorporates neck dissection to a policy of performing a neck dissection only in those patients whose imaging suggests a possibility of viable residual disease.
In addition to improvements in imaging to predict whether disease still remains, treatments have been intensified with the incorporation of chemotherapy, leading to higher response and disease control rates. 5, 6 As an example, Argiris et al demonstrated that among their patients with head and neck cancer who were treated with induction chemotherapy in addition to concurrent chemotherapy, there was a reduction in the lymph node positivity rate in neck dissection specimens. 7 These favorable results with various strategies of treatment intensification have been accompanied by the observation that more patients with head and neck cancer are presenting with human papillomavirus (HPV)-associated disease. 8 Several studies have demonstrated that patients with HPV-associated head and neck cancer (and specifically oropharyngeal cancer) have a disease that is more chemosensitive and radiosensitive, and disease control rates for patients with HPV-associated oropharyngeal cancer are significantly better than those noted in patients with oropharyngeal cancer that is not associated with HPV. 9, 10 Thus, improvements in imaging to detect viable disease, more intense treatment regimens, and a disease that is more sensitive to therapy have led many to eliminate a planned neck dissection from the overall treatment algorithm.
Despite the shift in management of the neck in patients with lymph node-positive disease toward a method that uses surgery only in those with a high suspicion of residual postradiation disease, to our knowledge few studies to date have focused on this strategy in patients with HPVassociated disease, a disease that presents with a very high percentage of lymph node positivity. We therefore performed the current study to assess the outcomes of patients with HPV-associated oropharyngeal cancer who were managed with radiotherapy (with or without chemotherapy) and with neck dissection reserved for patients in whom a concern remained for a high probability of residual disease.
MATERIALS AND METHODS
The database maintained by the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center (MDACC) in Houston was searched to identify patients treated with intensity-modulated radiotherapy (IMRT) for oropharyngeal carcinoma (squamous cell, poorly differentiated or undifferentiated, or not otherwise specified) who were irradiated between January 2006 and June 2012. The Institutional Review Board granted permission to conduct this retrospective study.
The search was further narrowed to exclude patients for the following reasons: distant metastases or concurrent malignancies (exclusive of a second malignancy of the oropharynx) at the time of diagnosis, a previously treated malignancy of the head and neck or previous radiotherapy to the head or neck, a history of any malignancy (excluding nonmelanomatous skin cancer) within 2 years of diagnosis, or treatment with chemotherapy before staging at MDACC.
Further inclusion criteria were then applied. The principal inclusion criterion was that the pathologic specimen was tested for either HPV or p16, and a positive result was obtained for one or the other. The second inclusion criterion was that the patient had lymphadenopathy at the time of diagnosis. Patients who had either excisional biopsies or a neck dissection and presented for their radiotherapy (6 chemotherapy) without macroscopic disease in the neck were excluded.
Medical records were reviewed to assess the patients' demographic, clinical, radiologic, and pathologic data.
Based on the medical history at the time of presentation and as described previously, 11 patients were classified as current smokers, former smokers, or never-smokers.
Patients' disease was staged according to the American Join Committee on Cancer (AJCC) 2002 staging system. 12 Charts were reviewed to verify tumor size and sites of invasion. Staging variables of interest included T classification, N classification, and overall AJCC group stage. Patients classified as Tx were typically those seen after tonsillectomy and if the tumor size could not be determined after record review, these patients were classified as T1 for the purpose of AJCC stage grouping in this analysis.
The overall treatment strategies were individualized for each patient. General treatment strategies were recommended at our multidisciplinary tumor board, although the specifics of treatment were performed by the patients' treatment team. Our general philosophy during the years of this study was to use concurrent chemotherapy for patients with bulky disease, principally disease of the primary site (large T2 to T4 disease). Induction therapy was recommended based on lymph node status, particularly for patients with multiple lymph nodes and lymph node disease in the lower levels of the neck. Selected patients with either prohibitive comorbidities or nonbulky disease with low T and N classifications were treated with radiotherapy alone despite nominally having advanced AJCC group staging.
Our approach to managing the lymph node-positive neck in patients with head and neck cancer has been described previously. 13 Decisions for neck dissection are deferred until treatment response is assessed clinically and radiographically. Infrequently, a planned neck dissection is decided on before initiating radiotherapy. This occurs in the uncommon situation in which a patient presents with bulky adenopathy in level 4, at which the lymph node disease is in close proximity to the brachial plexus. If necessary, we will accept a maximal dose of 66 gray (Gy) to the brachial plexus, and will treat subcentimeter lymph nodes to this dose, but will recommend a planned neck dissection for patients with bulkier disease in this location.
All patients were irradiated with IMRT. The methodology of treatment delivery, planning including target definition, and dose and fractionation schedules have been described. 11 The majority of patients were treated with once-daily fractionation to doses of 66 Gy to 70 Gy, at 2.2 Gy to 2.12 Gy per fraction. Occasionally, an accelerated schedule delivering 70 Gy to 72 Gy in 6 weeks with some twice-daily fractionation was used. For those patients treated to 66 Gy to the primary tumor, consideration for a 2-Gy to 4-Gy boost (with electrons) to the lymph nodes was made on an individual basis.
Statistical Analysis
Chi-square tests were used to compare proportions between subsets. Binary logistic regression was used to test the relationship between continuous variables and binary responses. The Kaplan-Meier method was used to calculate actuarial curves. Time of diagnosis was used as time 0. Patients without disease recurrence at the site of interest were censored at the time of last follow-up. Comparisons between survival curves were made using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model.
RESULTS

Patient, Disease, and Treatment Characteristics
Patient and tumor characteristics for the 401 patients who met the inclusion criteria are shown in Table 1 . Radiation doses ranged from 29 Gy to 74 Gy (median, 70 Gy). Only 4 patients received < 66 Gy; 1 patient died during treatment and 3 patients discontinued their treatment due to toxicity.
Neoadjuvant chemotherapy was delivered to 224 patients. All patients received regimens that were platinbased and taxane-based. The use of induction therapy was associated with neck stage, size of the largest lymph node, and lowest neck level (all P < .001). Only 5 patients (7%) with N1 to N2A disease received induction therapy. Approximately 92% of patients with level 4 disease had induction therapy compared with 76% and 35% of patients whose lowest lymph node levels were level 3 and 2, respectively. Chemotherapy was administered concurrently with radiotherapy in 267 patients. A singlet of cisplatin, carboplatin, or cetuximab was used in 246 patients. Eight additional patients had a singlet, but had their agent changed due to toxicity. Eight patients were treated on a protocol using vandetanib, 3 were treated with docetaxel, and 2 were treated on study with both cetuximab and cisplatin. The use of concurrent chemotherapy was not found to be associated with lymph node stage, size of largest lymph node, or lowest neck lymph node (P > .1).
Restaging After Radiotherapy
Initial restaging was performed with CT in 353 patients (88%), PET/CT in 18 patients (4%), and both contrast CT and PET/CT in 25 patients (6%). Four patients were not restaged, and 1 patient was reassessed outside MDACC and these data were not available. Initial restaging was performed 5 to 182 days after the completion of radiotherapy (mean, 58.4 days; median, 54 days).
CT was used as a component of restaging within 6 months of the completion of radiotherapy in 388 patients. The range of days from the completion of radiotherapy to the first restaging CT scan was 5 days to 182 days (median, 53 days). CT restaging was the only mode of reimaging in 139 patients (35%). PET restaging was performed 40 days to 175 days (median, 91 days) after the completion of radiotherapy in 199 patients, and 126 patients had an ultrasound of the neck 34 days to 180 days (median, 87 days) after radiotherapy. Ultrasonography was accompanied by fineneedle aspiration in 98 patients, and a positive specimen was obtained in 10 patients. Sixty-six patients underwent all 3 imaging modalities. There was no association noted between the use of additional imaging (to CT) with either initial lymph node staging or with the mode of systemic therapy.
Neck Dissection
A neck dissection was performed in 80 of the 401 patients (20%). Only 1 of these 80 patients underwent surgery on the primary tumor in addition to a neck dissection. Four patients had a planned neck dissection as part of their overall treatment strategy. The performance of neck dissection was associated with initial lymph node staging (P 5 .021), as a neck dissection was performed in 10% of N1 patients, 21% of N2 patients, and 30% of N3 patients. Although associated with lymph node stage, there was no association found between frequency of neck dissection and lymph node levels involved, even taking into account the 4 planned dissections that were performed because of concerns of high radiation dose to level 4 (and the brachial plexus). Neck dissection was performed in 27% of patients restaged with CT only compared with 17% of patients who underwent additional imaging (P 5 .002). Neck dissection was related to the time of initial restaging (P 5 .032) as the median number of days from the completion of therapy to restaging was 48.5 days for those undergoing a neck dissection compared with 54 days for those who did not undergo a neck dissection.
Positive specimens (viable tumor) were found in 21 of the 80 patients who underwent a postradiation neck dissection (26%). Lymph node size (largest lymph node measuring > or < 3cm), lymph node stage, and the chemotherapy mode were not associated with the finding of positive disease.
Original Article
Outcomes
The median follow-up time was 30 months (range, 2 months-76 months) for all patients, and 33 months (range, 4 months-76 months) for surviving patients. Fifty-two surviving patients (15%) had a follow-up of < 2 years, and only 4 of these patients had < 1 year of followup.
Thirty-one patients (8%) developed disease recurrence in the neck. Figure 1 charts the patients from the time of study entry through initial restaging, surgical management, and neck control. The actuarial 2-year and 5-year lymph node control rates were 93% and 90%, respectively. Nineteen of 378 patients (5%) with primary site control had neck recurrence with actuarial 2-year and 5-year lymph node control rates of 95% and 94%, respectively. Initial lymph node stage, size, or level were not found to be associated with disease recurrence. Neither chemotherapy mode (including none; P 5 .11) nor neck dissection (P 5 .4) were associated with disease recurrence. There was an association (P 5 .008) noted with smoking status, because the 2-year lymph node control rates for current, former, and never-smokers were 86%, 94%, and 95%, respectively.
The 19 patients with primary control and neck recurrence included 4 patients who underwent postradiation neck dissections; two of these dissections were positive for disease, and 2 were negative. All 4 had recurrences in the operated neck. Among the remaining 15 patients who had neck recurrences without neck surgery, 10 had recurrences in the epicenter of the principal dominant lymph node. One of these patients had persistent disease, but toxicity and comorbidities did not allow for neck dissection. Four patients presented with recurrence in sites that were irradiated to subclinical doses (50 Gy-63 Gy) because these sites were believed to be at risk but did not harbor disease. These sites included level 4 (and lung), level 1b, retropharynx, and contralateral neck. One patient had recurrence in an unirradiated and initially lymph node-negative contralateral neck.
DISCUSSION
The principle goal of the current study was to assess a strategy of neck dissection in patients with HPVassociated oropharyngeal cancer only for those who are believed to have residual disease after radiotherapy. This strategy was followed in > 99% of more than 400 patients, and the rate of disease recurrence in the neck was 8% and only 5% if the primary tumor was controlled. Not surprisingly, the incidence of neck dissection after radiotherapy did increase with tumor bulk (as defined by N classification), but the overall incidence even for patients with N3 disease was 30%. One observation is that compared with our prior experience of patients with oropharyngeal cancer who were treated with a similar strategy between 1996 and 2004, 13 the incidence of neck dissection after radiotherapy has decreased from 32% to 19%. Statistical testing of lymph node staging differences between the 2 experiences was not performed; however, 72% of our former patients had N2b disease or greater compared with 82% of the current cohort. The use of differing modes of integration of chemotherapy between this historic cohort and the current study population was comparable, and therefore it is unlikely that treatment factors impacted the neck dissection rate. In all likelihood, the favorable response rate of HPV-associated tumors is the explanation for a lower rate of neck dissection. A second hypothesis for the decrease in incidence may be the increase in posttherapy imaging with PET/CT and ultrasound complementing CT. We did note a decrease in the neck dissection rate of patients who had additional imaging to complement CT. However, this observation could be biased in that the data from the CT scans may have been sufficiently compelling to decide on neck dissection whereas additional imaging could have been obtained in cases in which the decision for neck dissection was equivocal. Furthermore, in a prospective study of posttreatment PET/CT scans, we concluded that among patients with HPV-associated disease, the gains of PET/CT in addition to conventional CT were small. 14 A third possibility is that the timing of reimaging may impact the use of neck dissection. Historically, neck dissection was recommended for patients with residual disease 6 weeks to 8 weeks after treatment. 15 Liauw et al described basing their decision for neck dissection on the findings of CT scans obtained 30 days after radiotherapy. The concept of delaying neck dissection until after PET was obtained 10 weeks to 12 weeks after treatment 16 was initially met with concerns, but the preponderance of data regarding the use of PET scans after therapy has obviated those fears. 17 The current study data suggest a relationship between the timing of imaging and the performance of a neck dissection. HPV-associated adenopathy often presents with a cystic inflammatory component, and progression of lymph node size during therapy has been noted to occur, 18 often due to an increase in this inflammatory component rather than tumor growth. Thus, it may take longer for these lymph nodes to regress 19 and our current surveillance program attempts to obtain initial imaging no less than 8 weeks after radiotherapy.
The patterns of disease recurrence raise further questions regarding the value of a uniform practice of neck dissection after radiotherapy. Ten of the 31 patients with lymph node recurrence either underwent or were unable to undergo neck dissection. Among the remaining 21 patients, 7 had primary recurrence, 1 had distant disease, and 5 had disease recur in areas of the neck that would unlikely have been included in a selective neck dissection. Thus, only 8 patients (2%) may have benefited from a neck dissection.
Although the current study results for patients with HPV-associated disease support not performing a neck dissection in > 80% of patients based on their response, the integration of neck dissection for these patients remains controversial. Specifically, the addition of neck dissection is being espoused in programs of treatment deintensification that advocate that a decrease in radiation dose by 5% to 10% combined with neck dissection may be better from a toxicity standpoint than from 66 Gy to 70 Gy (often with concurrent chemotherapy). 20 Frank et al described a small series of planned neck dissection post-radiation for their patients, limiting the radiation dose to 60 Gy. 21 Control rates were excellent and short-term toxicity was low, but to our knowledge longer follow-up has not been reported to date. More commonly, advocates of minimally invasive surgery for the primary tumor are combining this with neck dissection. 22 Infrequently, a patient with minimal disease can forgo radiotherapy, but the vast majority of patients with HPV-associated disease are lymph node positive, and will have either extracapsular disease or multiple lymph nodes that require radiation, 22 and therefore it remains moot whether this approach has a lower toxicity profile.
In conclusion, we describe an experience with a large cohort of patients with HPV-associated, lymph nodepositive oropharyngeal cancer who were treated with radiotherapy (and often chemotherapy) and had neck dissections performed based on response. The overall control rate of disease in the neck, and the patterns of recurrence, support this approach. The neck dissection rate was only 20%, and there was a suggestion that complementary imaging in addition to CT scans as well as the timing of the initial restaging imaging may have impacted this relatively low rate, although the relative radiosensitivity of HPV-associated disease was likely contributory as well.
Based on our experiences, we have attempted to formalize the postradiation follow-up schedule. Currently, we see patients for their first posttherapy tumor assessment at 8 weeks to 10 weeks with a contrast CT scan performed. Complementary imaging (ultrasound and/or PET) is obtained 4 weeks to 6 weeks later if a lymph node remnant of concern is present on contrast CT, and decisions regarding performing surgery or placing the patient on a routine surveillance program are made at that time.
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